Company profile

TMS company profile

TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.

Business identity

Contact email
[email protected]
Phone number
+81-42-306-5087
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$1K+
Founded
2005-02-17

Headquarters

Headquarters
Fuchu, Japan, Tokyo
Country code
JP
Continent
Asia

Capital profile

Funding and company signals

Funding rounds
4
Total equity funding
$7.3M
Last funding
Series Unknown / $266.9K / 2017-06-30
Last equity funding
Series Unknown / $266.9K
Investors
11
Lead investors
1
Founders
1
Articles
3

Founders and investors

Founders

Keiji Hasumi

Lead investors

77 Capital

Investors

KSPMitsubishi UFJ CapitalMITSUI SUMITOMO INSURANCE Venture Capital (MSIVC)Nissay CapitalOita Venture Capital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.